Kuros Biosciences was formed as a spin-off from the Swiss Federal Institute, ETHZ, and University of Zurich. Kuros aims to be a leader in the development of biologics and biomaterials for localized therapy within the core areas of sealants, orthobiologics and wound care. The product goal is to regenerate or restore the function of diseased and damaged tissue or to deliver a therapeutic locally.
Kuros merged with Cytos and is now listed as Kuros Biosciences Ltd. on the SIX Swiss Stock Exchange.
Learn more on https://kurosbio.com